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Background: Asymptomatic Peripheral Arterial Disease (PAD) is associated with greater risk of acute cardiovascular
events. This study aims to determine the cost-effectiveness of one time only PAD screening using Ankle Brachial
Index (ABI) test and subsequent anti platelet preventive treatment (low dose aspirin or clopidogrel) in individuals at
high risk for acute cardiovascular events compared to no screening and no treatment using decision analytic
modelling.
Methods: A probabilistic Markov model was developed to evaluate the life time cost-effectiveness of the strategy of
selective PAD screening and consequent preventive treatment compared to no screening and no preventive treatment.
The analysis was conducted from the Dutch societal perspective and to address decision uncertainty, probabilistic
sensitivity analysis was performed. Results were based on average values of 1000 Monte Carlo simulations and using
discount rates of 1.5% and 4% for effects and costs respectively. One way sensitivity analyses were performed to
identify the two most influential model parameters affecting model outputs. Then, a two way sensitivity analysis was
conducted for combinations of values tested for these two most influential parameters.
Results: For the PAD screening strategy, life years and quality adjusted life years gained were 21.79 and 15.66
respectively at a lifetime cost of 26,548 Euros. Compared to no screening and treatment (20.69 life years, 15.58 Quality
Adjusted Life Years, 28,052 Euros), these results indicate that PAD screening and treatment is a dominant strategy. The
cost effectiveness acceptability curves show 88% probability of PAD screening being cost effective at the Willingness To
Pay (WTP) threshold of 40000 Euros. In a scenario analysis using clopidogrel as an alternative anti-platelet drug, PAD
screening strategy remained dominant.
Conclusion: This decision analysis suggests that targeted ABI screening and consequent secondary prevention of
cardiovascular events using low dose aspirin or clopidogrel in the identified patients is a cost-effective strategy.
Implementation of targeted PAD screening and subsequent treatment in primary care practices and in public health
programs is likely to improve the societal health and to save health care costs by reducing catastrophic cardiovascular
events.
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Peripheral Arterial Disease (PAD) is a common disorder
with a prevalence estimated at 16% in those aged over
55 years and 29% in high-risk groups [1,2]. PAD is a sign
of widespread atherosclerosis also affecting coronary,
cerebral and renal arteries. PAD is associated with a* Correspondence: a.vaidya@maastrichtuniversity.nl
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stated.significant reduction in Quality of Life (QoL) and greater
risk of acute cardiovascular events [3,4]. The increased
risk for cardiovascular morbidity, such as myocardial in-
farction and stroke, and increased risk for mortality is
also observed in asymptomatic patients [5]. The Cardio-
vascular consequences of PAD, are known to be expen-
sive and contribute substantially to national health care
costs [6].
European Society of Cardiology (ESC), American Heart
Association (AHA) and American College of Cardiology
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in symptomatic PAD patients [7,8]. Clopidogrel is re-
commended as an effective alternative anti-platelet the-
rapy to aspirin for secondary prevention in PAD [8].
Ankle Brachial Index (ABI) is used for detection of PAD.
The ABI is calculated by measuring both arm and leg
blood pressure (at ankle level). This reliable and inexpen-
sive test is highly sensitive and specific for PAD. However,
ABI screening in asymptomatic patients is a controversial
topic among the health professionals. United States
preventive services task force (USPSTF) assigned a “D”
recommendation to the routine screening of PAD [9].
This recommendation is intensely debated and a routine
targeted screening for PAD is recommended to increase
the frequency of diagnosis, improve the use of re-
commended medical therapies, and consequently reduce
cardiovascular morbidity and mortality rates [10]. Re-
searchers have voiced that ‘it’s not just about legs’ and ABI
measurement in asymptomatic individuals should be
regarded as the biomarker of cardiovascular disease risk
[11]. While expansion of the evidence base for PAD
screening is recommended in the year 2011 focussed up-
date of the guidelines [12], targeted ABI screening is
recommended by all professional vascular societies inclu-
ding the ACC [8].
The Rotterdam study has identified risk factors that
are most strongly associated with PAD such as older
age, cigarette smoking, diabetes mellitus, hypercholeste-
rolemia and hypertension [13]. These risk factors can be
used to guide targeted ABI screening in a general popu-
lation over 55 years of age.
In current health care practice, asymptomatic PAD
often remains undiagnosed and opportunities for se-
condary prevention are missed [2]. Therefore, there is a
clinical need of early detection of asymptomatic PAD
and for the initiation the appropriate preventive treat-
ment in a high risk population. Although, prevention
and subsequent treatment comes at a certain cost the
secondary prevention of cardio-vascular consequences in
PAD patients may at the same time improve prognosis
and save healthcare resources. This study aims to deter-
mine the cost-effectiveness of PAD screening using ABI
and subsequent preventive treatment in high risk indi-
viduals at high risk for acute cardiovascular events with
low dose aspirin or clopidogrel compared to no scree-
ning and treatment.Methods
A model-based economic evaluation of targeted ABI
screening in high-risk group was performed taking life-
time costs and health effects in account for a Dutch
health care setting. Microsoft Excel 2010© software was
used for this modelling work.Future costs and outcomes were discounted at the rates
of 4% and 1.5% respectively, as per the Dutch guidelines
for pharmaco-economic research [14]. This study was
conducted from the societal perspective and indirect costs
(productivity loss) were taken into account.
Model approach
The hypothetical population consists of asymptomatic
males and females aged 55 years with at least one of the
vascular risk factors identified in the Rotterdam study [13].
The intervention is one time screening in a high risk
population at the age of 55 years using ABI, the current
standard test to detect PAD in primary care. Screening
in principle is intended to take place in the general prac-
titioner’s office, in a similar manner as ‘The prevention
visit’ for the cardiovascular risk assessment, defined in
the Dutch College of General Practitioners' practice
guideline [15]. We modelled that all ABI test positive
patients will receive preventive treatment with low dose
aspirin in the base case analysis. In a scenario analysis
low dose aspirin is replaced with clopidogrel as preven-
tive treatment in patients with a positive test.
ABI screening is compared to no screening of the high
risk population and preventive treatment is only given to
the incidentally diagnosed or incidentally symptomatic
patients. Model Outcomes were life years (LYs), quality
adjusted life years (QALYs) and costs. The model has a
time horizon of a life time as the hypothetical patient
cohort was followed until death. The model cycle du-
ration was one year.
Model structure
Based on a systematic review of modelling approaches
for PAD, we used a combination of two modelling ap-
proaches: a decision tree and a Markov state transition
model shown in the Figure 1 and Figure 2 [16]. The
decision tree was used to determine the number of
screened individuals falling into the categories of test
positive or test negative on the basis of test accuracy and
prevalence of PAD. A Markov model was subsequently
used to model the on-going risk of cardiovascular events
over a lifetime.
The model assumes that the patient is always in one of
a finite number of states of health referred to as Markov
states. The time horizon of the analysis is divided into
equal increments of time, referred to as Markov cycles,
in this case one year. During each cycle, the cohort of
patients is redistributed over the Markov states, thus
theoretically a patient may make a transition from one
state to another. Each state is assigned a utility and a
cost. Total costs and utility for screening versus no-
screening are calculated depending upon the distribution
of the cohort over the Markov states and the length of
time spent in each state [17].
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states in the Markov model (no PAD, asymptomatic
PAD, and symptomatic PAD, post amputation, post
myocardial infarction, post stroke, post bleed-in treated
patients and the absorbing state of death). Risk reduc-
tions of cardiovascular events and mortality as well as
increased bleeding risk caused by the preventive anti-
platelet treatment were modelled accordingly in our
model. All the model parameters are shown in Table 1.
Transition probabilities
Transition probabilities for PAD patients were calculated
from the REACH (Reduction of Athero-thrombosis for
Continued Health) registry. This multinational database
contains 68,375 consecutive outpatients from 5587 phy-
sician practices in 44 countries and was enrolled be-
tween December 2003 and June 2004 [24]. Patients on
anti-platelet preventive treatment have reduced cardio-
vascular morbidity and mortality but on the other hand
this treatment increases the risk of bleeding in the reci-
pients. Transition probabilities for cardiovascular events
in patients receiving Aspirin were calculated from
a meta-analysis of randomised trials ‘Aspirin for the
Prevention of Cardiovascular Events in Patients With Peri-
pheral Artery Disease’ [26]. Probabilities for Clopidogrel
were calculated from a Cochrane review of anti-platelet
agents for intermittent claudication [28]. Bleeding risks in
patients receiving low dose aspirin or clopidogrel were
assigned from a randomized, blinded, trial of clopidogrel
versus aspirin in patients at risk of ischemic events
(CAPRIE) [27].
Costs
The acute phase costs and subsequent costs of cardio-
vascular events were taken from Thurston et al. [21] and
the costs of amputation and of cardiovascular death are
from Oostenbrink et al. [20]. The annual costs for an
average PAD patient were published by van Asselt et al.
[18] Dutch costs of anti-platelet medications aspirin and
clopidogrel were obtained from the medicine cost web-
site in the Netherlands [19]. Travel costs for attending
the PAD screening were calculated based on the average
distance to a primary practice. The average distance to a
Dutch primary practice is 1.1 KM [32]. Cost of a session
at a primary care physician and productivity loss for a 55
years old individual in the Netherlands are published in
the Dutch manual for costing in economic evaluations
[33]. All costs used in the model were converted to Year
2012 Dutch costs using harmonized index of consumer
prices data from the Dutch bureau of statistics [34].
Utilities
Since Dutch utility scores for the health states defined in
our model were not found in the literature, we usedSullivan et al. to estimate utilities for all the health states
except amputation [30]. The utility of an amputee using
standard gamble method was taken from Berry et al. [31].
Analysis
Discounted and undiscounted expected life years and
QALYs (1.5% discount rate), and costs (discount rate
4%) for each strategy were calculated. Based on the dis-
counted expected values, the Incremental Cost Effec-
tiveness Ratios (ICERs) of the screening and treatment
strategy were calculated over the standard existing prac-
tice of no screening and preventive treatment with low
dose aspirin for incidentally diagnosed or symptomatic
patients only.
The results of cost-effectiveness analysis were based on
Probabilistic Sensitivity Analysis (PSA). Results of 1000
Monte Carlo simulations were graphically displayed in the
form of cost-effectiveness planes (CE planes) and the sub-
sequent probability of being cost-effective at different
values of willingness to pay (WTP) thresholds was shown
as cost-effectiveness acceptability curves (CEACs).
One way sensitivity analyses were performed to iden-
tify the two most influential model parameters affecting
model outputs. For this purpose, upper and lower limits
of 95% confidence interval of model parameters were
used. Then, a two way sensitivity analysis was conducted
for combinations of values tested for these two most
influential parameters.
Scenario analysis
We performed a scenario analysis by replacing routinely
prescribed low dose aspirin with a relatively new anti-
platelet drug clopidogrel for the secondary prevention of
cardiovascular events in identified PAD patients.
Results
Cost-effectiveness analysis
The expected model outcomes show that the targeted
ABI screening and treatment with low dose aspirin pro-
duce 21.79 mean LYs and 15.66 mean QALYs for a cost
of 26,548 Euros. The cost of PAD screening and treat-
ment followed by low dose aspirin was 1503 Euros lower
compared to ‘no screening’ and 0.07 QALYs were gained
(Table 2). Therefore, ABI screening followed by preven-
tive treatment with low dose aspirin is a dominant stra-
tegy. The relationship between costs and effects and the
uncertainty surrounding these estimates are shown in
the cost effectiveness planes in the Figure 3. Monte
Carlo simulation shows that the 88% of ICER dots are in
the right lower quadrant indicating that the strategy
‘PAD screening’ tended to have favourable health out-
comes against lower costs in comparison with a strategy
of ‘no screening’. The probability of being cost effective
at different values of willingness to pay (WTP) thresholds
Table 1 Model parameters and distribution used in the probabilistic sensitivity analyses
Model parameter Value Probability distribution Moments of the probability
distribution ά/min, β/max
Source
Discount rates
Cost discount rate 4% Fixed - [14]
Outcome discount rate 1.5% Fixed - [14]
Costs (Euros)*
Cost of ankle brachial index test 74† BETA Pert 55.7;92.8 MUMC‡
Annual cost of PAD treatment 2369 GAMMA 325.09;7.29 [18]
Annual cost of Aspirin 10 Fixed [19]
Annual cost of Clopidogrel 19 Fixed [19]
Costs of Amputation 14343† BETA Pert 10683;17804 [20]
Cost of AMI in first year 25328 GAMMA 100;253.27 [21]
Annual costs of MI treatment in subsequent years 3584 GAMMA 99.92;35.86 [21]
Cost of stroke in first year 27964 GAMMA 99.99;279.66 [21]
Annual costs of treatment of stroke in subsequent years 10646 GAMMA 99.99;106.47 [21]
Costs of bleeding 3457 GAMMA 99.87;34.61 [21]
ABI test accuracy
Sensitivity 0.90† BETA Pert 0.68;1 [22]
Specificity 0.95† BETA Pert 0.71;1 [22]
Incidence/prevalence of PAD
Prevalence of PAD 0.184 BETA 1372;6082 [6]
Annual incidence of PAD in 55–64 years aged 0.005 BETA See Additional file 1 [23]
Annual incidence of PAD in 65–74 years aged 0.007 BETA See Additional file 1 [23]
Annual incidence of PAD in 75–84 years aged 0.008 BETA See Additional file 1 [23]
Annual incidence of PAD in >85 years aged 0.010 BETA See Additional file 1 [23]
Event probabilities
Probability of amputation in patients with no PAD 0.003 BETA 32;11734 [24]
Probability of AMI in patients with no PAD 0.008 BETA 89;11677 [24]
Probability of stroke in patients with no PAD 0.008 BETA 94;11672 [24]
Probability of amputation in PAD patients 0.016 BETA 140;8441 [24]
Probability of AMI in PAD patients 0.013 BETA 111;8470 [24]
Probability of stroke in PAD patients 0.019 BETA 165;8416 [24]
Probability of symptomatic PAD 0.3 BETA 138;320 [25]
Relative risk in PAD patients on low dose aspirin 0.78 BETA 25.45;7.2 [26]
Probability of bleeding in PAD patients on aspirin 0.026 BETA 255;9311 [27]
Relative risk in PAD patients on Clopidogrel 0.616 BETA See Additional file 1 [28]
Probability of bleeding in PAD patients on Clopidogrel 0.020 BETA 191;9386 [27]
Mortality in ‘untreated’ patients
Annual probability of death in PAD patients 0.037 BETA 323;8258 [24]
Probability of death in post Amputation 0.155 BETA 4297;21281 [29]
annual probability of death in post MI alive patients 0.028 BETA 521;17492 [24]
annual probability of death in post stroke alive patients 0.031 BETA 1212;37390 [24]
Utility
PAD 0.652 BETA 0.8;0.4 [30]
Amputation 0.45 BETA 210.8;257.7 [31]
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Table 1 Model parameters and distribution used in the probabilistic sensitivity analyses (Continued)
Post MI 0.671 BETA 69.3;34 [30]
Post stroke 0.519 BETA 2.7;2.5 [30]
Post bleed 0.627 BETA 405.6;241.13 [30]
*All costs were converted to 2012 Dutch costs using harmonized index of consumer prices (HICP).
‡This cost was obtained from the Financial department of Maastricht University Medical Centre.
†Mode for BETA Pert distribution.
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(CEACs) in the Figure 4. The curves show the proba-
bility of PAD screening being cost effective at a range of
Willingness To Pay thresholds. There is 88% probability
of PAD screening being cost effective at the WTP of
40000 Euros.
Scenario analysis with the use of clopidogrel as an al-
ternative anti-platelet therapy produced similar results
indicating dominance over ‘no screening’ (Table 2).
The one way sensitivity analysis identified PAD preva-
lence and relative risk reduction by low dose aspirin in the
treated PAD patients, as the two most influential model
parameters. Although the ICER for ABI screening re-
mained dominant for all the variations in parameter
values, two way sensitivity analysis varying PAD preva-
lence and relative risk reduction by aspirin showed a con-
sistent QALY gain by either increasing the prevalence of
PAD or relative risk reduction by low dose aspirin.
Discussion
Our cost-effectiveness model output suggests that targeted
screening of high risk individuals and consequent secon-
dary prevention of cardiovascular events by anti-platelet
medication is cost effective and results in significant health
gain by reducing cardiovascular events in PAD patients.Table 2 Results – base case analysis and scenario analysis
PROBABILISTIC RESU
Diagnostic test Treatment Costs LYs
Base case
No screen Low dose aspirin 28052 20.69
ABI screening Low dose aspirin 26548 21.79
Scenario analysis with Clopidogrel
No screen Clopidogrel 29464 22.33
ABI Clopidogrel 27681 22.57
PROBABILISTIC RESULTS (undiscounted)
Diagnostic test Treatment Costs LYs
Base case
No screen Low dose aspirin 63155 26.32
ABI screening Low dose aspirin 59544 27.47
Scenario analysis with Clopidogrel
No screen Clopidogrel 67799 28.30
ABI Clopidogrel 63759 28.66The analysis has been performed from societal per-
spective and all direct and indirect costs are incorpo-
rated for all the health states in the model. Our analysis
interprets that PAD screening and anti-platelet prevent-
ive treatment is a highly cost-effective intervention.
Changing the analysis perspective to health care payer’s,
would further strengthen this interpretation. This is the
case in countries like the United Kingdom where health
care is financed by general taxation, a health care pro-
vider’s (National Health Services) perspective is used in
pharmaco-economic analyses and only direct costs are
covered.
A recent meta-analysis concluded that measurement
of the ankle brachial index may improve the accuracy of
cardiovascular risk prediction beyond the Framingham
Risk Score [35]. After adjustment for the Framingham
risk score, the ABI provided significant improvement in
predicting cardiovascular risk independent of established
risk factors in a broad population. There is unequivocal
evidence establishing the importance of targeted ABI
screening [36,37].
In our model costs and effects were modeled for as-
pirin and clopidogrel. The CAPRIE trial data show that
clopidogrel is more effective than aspirin in reducing
cardiovascular events in the subgroup of patients withLTS (discounted)
QALYs iCosts iLY iQALYs iCERs
15.58
15.66 −1503 1.10 0.007 Dominant
15.95
16.17 −1783 0.24 0.22 Dominant
QALYs iCosts iLY iQALYs
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-4000
-3500
-3000
-2500
-2000
-1500
-1000
-500
0
500
1000
-0.40 -0.20 0.00 0.20 0.40 0.60 0.80 1.00
i
C
o
s
t
s
iQALYs
ABI
Figure 3 incremental Cost-effectiveness planes. Shows that PAD screening followed by low dose aspirin treatment was a dominant strategy
(less costly, more effective) in 88% of simulations.
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Figure 4 Cost-effectiveness acceptability curves. The acceptability curves show that ABI Screening followed by treatment with low dose
aspirin remains 100% cost-effective at willingness to pay (WTP) thresholds of zero to 11000 Euros and 88% cost-effective at a WTP threshold of
40000 Euros.
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cost was a major barrier for longer-term use. Plavix (clopi-
dogrel) lost its patent protection from May 2012 and the
generic form of clopidogrel is available at a much lower
cost. Since branded Plavix may have been cost-prohibitive
in certain non-reimbursement settings, there will likely be
an increase in compliance with long-term generic clopi-
dogrel therapy. Economic model results for the use of
clopidogrel in PAD patients were in line with previous
studies establishing the cost-effectiveness of this drug
[38,39]. These results were expected as generic clopidogrel
costs only few Euros more than aspirin and provides
higher risk reduction from C The limitation of our model
is that the costs and health outcomes of only antiplatelet
treatment are modeled. Depending upon the identified
risk factors in the individual patients many additional
medication interventions such as statins and tension low-
ering medications are prescribed for the medical manage-
ment of PAD. However, our study focusses on antiplatelet
treatment using Aspirin or Clopidogrel as this is the most
commonly prescribed medication in almost all the pa-
tients. In order to model the additional therapies for each
subgroup of high risk patients a much more complex
model is needed.
ABI has been in wide use at specialized vascular
clinics but its application in primary practice is limited.
With a high degree of diagnostic accuracy and as much
prognostic information, ABI screening is a cost-effective
but underused primary care tool to detect PAD. Mohler
et al. found that the time to perform ABI, staff con-
strains and lack of reimbursement are the most impor-
tant barriers in its use and appropriate measures are
required to deal with these barriers [40]. However, this
cost-effective analysis clearly indicates that the ABI
screening is a highly cost-effective clinical tool to be ap-
plied in the primary care.
In the real world scenario, compliance to the ABI
screening and to the preventive treatment thereafter, in
an apparently healthy population could pose a chal-
lenge. However, factors like the noninvasive nature of
the ABI testing and routine primary care visits of high
risk individuals are likely to contribute to good com-
pliance. Although lower compliance to the screening
programme may affect the overall cost effectiveness re-
sults, it is unlikely to negate the cost-effectiveness of
ABI screening altogether because of the high probability
of the screening programme to be cost-effective as
shown in the cost-effectiveness plane (Figure 4).
Our results are in line with a previously published
modeling study by Sigvant et al. to assess the cost-
effectiveness of various therapeutic agents in asymp-
tomatic PAD patients. Aspirin as one of the preventive
therapies produced similar health outcomes in 55 year-
old patients as our model [41].In line with ACC/AHA guidelines, this modeling study
is only based upon risk reduction by preventive anti-
platelet therapy given to the PAD patients. Additional
cardiovascular risk reducing treatments such as exercise
therapy, lipid lowering statins and blood pressure lowe-
ring drugs are also prescribed in PAD. Further research
is required to quantify the consolidated effects of diverse
preventive options in a heterogenic PAD population.
Conclusions
This study has assessed the impact of PAD screening
using long term clinical and economic outcomes. The re-
sults show that targeted ABI screening and consequent
secondary prevention of cardiovascular events using low
dose aspirin or clopidogrel is a cost-effective strategy. Our
study results provide one of the building blocks of evi-
dence expansion for advocating PAD screening and the
promotion of its more widespread use to detect and treat
PAD patients. Implementation of targeted PAD screening
and subsequent treatment in primary care practices and in
public health programs is likely to improve the societal
health and to save health care costs by reducing cata-
strophic cardiovascular events.
Additional file
Additional file 1: Calculation of probabilistic moments for PAD
Incidence.
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